Paper
- Alzforum Recommends
Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol. 2001 Aug;159(2):439-47. PubMed.
Recommends
Please login to recommend the paper.
Comments
Washington University
The data in the paper by Sigurdsson et al. are convinced that the immunization
protocol they used is effective in decreasing plaque burden in the Tg2576 (also
called APPsw) mouse model of AD. They present nice evidence that the peptide
with which they immunized the mice does not become fibrillar in the assays they
used. This is important as it makes it likely that the antibodies generated
by the immunized mice are likely to be recognizing soluble and not just insoluble
forms of Aβ very well.
If immunization ends up being a treatment to prevent or treat AD, it is not
View all comments by David Holtzmanyet clear whether immunizing with soluble or fibrillar forms or Aβ will
be better in humans. Sigurdsson, et al., bring up the possible advantages of utilizing
a soluble, nontoxic fragment of Aβ. Whether or not these potential advantages
turn out to be correct, their work is important because it simply is not clear
yet, until trials are done in humans, which of the immunization protocols will
not only be effective but also demonstrate the least toxicity.
Boston University School of Medicine
This provides further confirmation of the value of immunization in reducing amyloid burden.
Make a Comment
To make a comment you must login or register.